Literature DB >> 24998538

Radiotherapy for ovarian cancers - redefining the role.

Bhavana Rai1, Anshuma Bansal, Firuza Darius Patel, Suresh Chander Sharma.   

Abstract

Radiation therapy in ovarian cancers has been considered an outdated concept for many years, mainly due to toxicity and failure to show benefit in terms of survival. Chemotherapy has been extensively used after surgery for these cancers and it has almost replaced radiation therapy as an adjuvant treatment. Nevertheless, failures in ovarian cancers continue to occur even with the use of newer and effective chemotherapy regimens. About 70% patients demonstrate recurrence in the abdomen or pelvis after first line chemotherapy in ovarian cancers. With advances in technology and sophistication of radiation techniques, along with the molecular and biological knowledge of distinct histological subtypes, there is a need to redefine the role of radiation therapy. This review article focuses on the literature on use of radiation in ovarian cancers and its rationale and indications in the present day. For this, a literature pub med/medline search was performed from January 1975 to March 2014 to redefine the role of radiotherapy in ovarian cancers.

Entities:  

Mesh:

Year:  2014        PMID: 24998538     DOI: 10.7314/apjcp.2014.15.12.4759

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional Experience.

Authors:  Anshuma Bansal; Bhavana Rai; Shikhar Kumar; Vanita Suri; Sushmita Ghoshal
Journal:  J Obstet Gynaecol India       Date:  2016-07-29

2.  Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011.

Authors:  Sagar C Patel; Jonathan Frandsen; Sudershan Bhatia; David Gaffney
Journal:  J Gynecol Oncol       Date:  2016-05-03       Impact factor: 4.401

3.  Stereotactic body radiation therapy in the treatment of ovarian cancer.

Authors:  Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; William P Irvin; Charles R Kersh
Journal:  Radiat Oncol       Date:  2020-05-13       Impact factor: 3.481

4.  Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.

Authors:  Lili Zhao; Shihai Liu; Donghai Liang; Tao Jiang; Xiaoyan Yan; Shengnan Zhao; Yuanwei Liu; Wei Zhao; Hongsheng Yu
Journal:  Cancer Med       Date:  2019-04-02       Impact factor: 4.452

5.  miR-214 promotes radioresistance in human ovarian cancer cells by targeting PETN.

Authors:  Qin Zhang; Shuxiang Zhang
Journal:  Biosci Rep       Date:  2017-07-04       Impact factor: 3.840

6.  Betulinic Acid Suppresses Ovarian Cancer Cell Proliferation through Induction of Apoptosis.

Authors:  Dahae Lee; Seoung Rak Lee; Ki Sung Kang; Yuri Ko; Changhyun Pang; Noriko Yamabe; Ki Hyun Kim
Journal:  Biomolecules       Date:  2019-07-03

7.  miR-4478 sensitizes ovarian cancer cells to irradiation by inhibiting Fus and attenuating autophagy.

Authors:  Lingling Wang; Ying Liu; Haixia Li; Cui Zhang; Hongbo Wang; Shaochun Dai; Wen Cheng; Yan Sun; Xiulan Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2020-12-03       Impact factor: 8.886

8.  Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification.

Authors:  Jing Shen; Yin Jie Tao; Hui Guan; Hong Nan Zhen; Ting Ting Dong; Zhi Kai Liu; Fu Quan Zhang
Journal:  World J Oncol       Date:  2022-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.